THANK YOU FOR SUBSCRIBING
Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
The new financing round allows IME to further capitalize on its scientific and technical findings, growing its product portfolio from regenerative medtech solutions to promising global market for targeted drug delivery solutions.
Judith Heikoop, CEO
FREMONT, CA: IME Medical Electrospinning, a leader in electrospun medical devices and regenerative medicine, announces that it has successfully raised €3 million in equity financing and debt from existing shareholders TIIN Capital, new investors Borski Fund and Lumana Invest, and from Rabobank Region Eindhoven.
IME launched the MediSpin XL production platform in 2019 for large-scale industrial manufacturing of reproducible and scalable electrospun nanofiber-based scaffolds for Class I, II, and III medical devices, marking an international breakthrough in the large-scale controlled production of batch-consistent, high-quality end-products in volume. Managing the electrospinning control parameters unlocks its full ability for industrial, medical applications.
MediSpin XL generates nanometer solutions that mimic the natural extracellular matrix in the human body. Human cells identify and infiltrate these scaffolds, encouraging fast and efficient tissue integration, resulting in natural tissue restoration while mitigating medical complications. The innovative applications include fully bioresorbable stents, heart valves, nanofibrous meshes, and several new devices for a.o. local drug delivery, implantables, and tissue engineering.
The additional financing and support of new shareholders Borski Fund, Lumana Invest, and existing shareholder TIIN Capital will let IME to further strengthen its MediSpin XL electrospinning platform and industrial production abilities for medical devices and drug delivery applications. Integrating IME’s state of the art production platform with its broadened focus underpins the company’s strong belief in the strategic goal of becoming the frontier in large-scale production of both medical devices and drug delivery solutions. Now, the firms can jointly develop other breakthrough medical solutions with their pharma partners and expand their operations.
IME Medical Electrospinning has been a key player in the field of developing and implementing electrospinning processes and devices for the manufacturing of medical devices for medicine and drug delivery. Its customers and scientific partners are MedTech and Pharma industry, scientists, and health institutions.
Read Also
